DiaSorin S.p.A. · MIL:DIA
DiaSorin — Q3 2026 Earnings Presentation
22 slides from DiaSorin's earnings presentation, Nov 12, 2026
Slide 1: Q3 & 9M 2026 Results
Q3 & 9M 2026 RESULTS November 12, 2026
Slide 2: Disclaimer
DISCLAIMER In General. This disclaimer applies to this presentation and any oral No distribution of this Presentation. This Presentation is being furnished to comments of any person presenting it. This document, taken together you solely for your information and may not be reproduced, in whole or in
Slide 3: Forward-Looking Statements
FORWARD-LOOKING STATEMENTS This document contains forward-looking statements that are based on current expectations, estimates, forecasts and projections about the industries in which Diasorin operates and the beliefs and assumptions of the management of Diasorin. In addition, the management of Dias
Slide 4: Business Highlights
BUSINESS HIGHLIGHTS 6) Diasorin
Slide 5: Business Highlights
Business Highlights Jan Feb Mar Apr May Jun Oct Nov 2026 2026 2026 2026 2026 2026 2026 2026 LIAISON LIAISON Parvovirus B19 Delta Hepatitis QuantiFERON- IgM Plus &IgG U.S. Market TB Gold Plus II Plus U.S. Market U.S. Market Authorization Commercial LIAISON PLEX LIAISON PLEX request Launch Gastro- LIA
Slide 6: Financial Highlights
FINANCIAL HIGHLIGHTS 6) Diasorin
Slide 7: Q3'26 & 9M'26 Revenue Variances at Constant Exchange Rates 2025
Q3’26 & 9M’26 Revenue Variances at Constant Exchange Rates 2025 Q3’26 Group revenues (figures in €/million) 9M’26 Group revenues (figures in €/million) 45 +19% 130 +5% 9M’26 51 Q3’26 Q3’26 147 308 +11% 9M’26 -1% +3% +8% 910 213 632 +5% +3% Immunodiagnostics Immunodiagnostics Molecular Diagnostics Mo
Slide 8: Q3'26 & 9M'26 Immunodiagnostic Revenue Variances At Constant Exchange Rates 2025
Q3’26 & 9M’26 Immunodiagnostic Revenue Variances At Constant Exchange Rates 2025 Q3’26 revenues (figures in €/million) 9M’26 revenues (figures in €/million) Base Business (ex-China) in Q3’26: China • Growth accelerating QoQ, in line with expectations, in particular CLIA franchise . • Slightly improv
Slide 9: Q3'26 & 9M'26 Molecular Diagnostic Revenue Variances At Constant Exchange Rates 2025
Q3’26 & 9M’26 Molecular Diagnostic Revenue Variances At Constant Exchange Rates 2025 Q3’26 revenues (figures in €/million) 9M’26 revenues (figures in €/million) Lowplex Multiplex Lowplex Multiplex Automated multiplexing: LIAISON MDX targeted: • Excellent performance of automated multiplexing driven
Slide 10: Automated Multiplexing: LIAISON PLEX
Automated Multiplexing: LIAISON PLEX LIAISON PLEX CUSTOMERS: ca. 170 (65% flex vs. 35% fixed) BY NUMBER OF CUSTOMERS BY REVENUE CONTRIBUTION • 10% commercial labs • 30% commercial labs • 90% hospital labs • 70% hospital labs LIAISON PLEX COMMERCIAL LAUNCH UPDATE: • Commercial team fully established
Slide 11: Q3'26 & 9M'26 LTG Revenue Variances At Constant Exchange Rates 2025
Q3’26 & 9M’26 LTG Revenue Variances At Constant Exchange Rates 2025 Q3’26 revenues (figures in €/million) 9M’26 revenues (figures in €/million) Life Science clients: • Improving market conditions in particular in the research environment in the US Diagnostics clients: • In line with 2025 on a 9 mont
Slide 12: Q3'26 & 9M'26 Profitability Profile
Q3’26 & 9M’26 Profitability Profile Net Revenues and Adj. EBITDA data @ current exchange rates; Adj. EBITDA Margin @ constant exchange rates. 32% 34% 280 308 89 103 Net Revenues In Q3 2026, the ratio to revenues stood at 34% at constant exchange rates, and 33% at current exchange rates confirming th
Slide 13: FY 2026 Company Guidance and 2026 Outlook
FY 2026 COMPANY GUIDANCE AND 2026 OUTLOOK
Slide 14: FY'26 Guidance Confirmed
FY’26 Guidance Confirmed FY’26 GUIDANCE (@CER 2025) Revenues : Between +5% and +6% Adjust ed 1 EBITDA 2 Margin : approx. 32% - 33% CERPY Spot EUR/USD FX: 1.05 Avg. Expected 2026 EUR/USD FX: 1.18 (Source: Bloomberg) as of May 7, 2026 1 cent of difference between EUR and USD over 12 months has an impa
Slide 15: FY'26 Top Line Guidance @CER2025
FY’26 Top Line Guidance @CER2025 Revenue Guidance FY’26 Between +5% and +6% 1,195 €/mln • LTG: diagnostic customers are expected to grow at a LSD-to-MSD% rate, +LSD% offsetting the continued weakness in the Life Science business. LTG 165 €/mln • Molecular Diagnostics: growth driven by the launch of
Slide 16: FY'26 Growth Trajectory by Quarter
FY’26 Growth Trajectory by Quarter 1Q26 2Q26 3Q26 4Q26 • Immunodiagnostics: steady growth across different quarters in FY’26 as a result of the unique specialty menu and the hospital strategy, partially compensated by the normalization of volumes in Europe, with the exception of some tough compariso
Slide 17: Financial Schemes
FINANCIAL SCHEMES | 6) Diasorin
Slide 18: Income Statement
Income Statement Q3 Change 9 months Change Amounts in millions of euros 2025 2026 amount % 2025 2026 amount % Net Revenues 280.4 308.0 +28 +10% 899.7 909.6 +10 +1% Cost of sales (99.4) (110.6) -11 +11% (312.8) (322.8) -10 +3% Gross profit 181.0 197.4 +16 +9% 586.9 586.8 -0 -0% 65% 64% -45 bps 65% 65
Slide 19: Balance Sheet
Balance Sheet Amounts in millions of euros 12/31/2025 30/09/2026 Change Goodwill and intangibles assets 1,790.0 1,828.7 +39 Property, plant and equipment 255.9 274.9 +19 Other non-current assets 42.3 41.6 -1 Net working capital 325.2 371.1 +46 Other non-current liabilities (256.6) (267.9) -11 Net In
Slide 20: Cash Flow Statement
Cash Flow Statement Q3 9 months Amounts in millions of euros 2025 2026 2025 2026 Cash and cash equivalents at the beginning of the period 173.1 120.8 344.3 165.8 Cash provided by operating activities 114.6 96.5 259.6 205.8 Cash provided/(used) in investing activities (80.1) (28.7) (107.8) (41.6) Cas
Slide 21: September 2026 Reconciliation to Consolidated Financial Statements
September 2026 Reconciliation to Consolidated Financial Statements Amounbts in millions of euros Gross Profit EBITDA EBIT Net Result Financial Statements Measures 587 288 192 126 % on Revenues 65% 32% 21% 14% Adjustments “One-off” costs related to non recurring events 1 9 8 8 Depreciation of Luminex
Slide 22: Slide 22